Health TrialsbyHealthPanel

Tuberculosis Clinical Registry in Europe

ConditionTuberculosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorResearch Center Borstel

About this trial

The TBnet registry is a multinational, prospective tuberculosis registry established by the Tuberculosis Network European Trialsgroup (TBnet e.V.) to collect and analyze long-term data from TB patients across Europe. Its purpose is to centralize data on TB epidemiology, prevention, diagnosis, and treatment to improve care, support research, and ultimately help eliminate TB. The registry captures risk factors, diagnostic details (e.g., microbiology, imaging, drug resistance), treatment data, side effects, outcomes, and late complications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of Tuberculosis

Age ≥ 18 years

Capacity to provide informed consent

Written informed consent to participate in the study

Disqualifiers

Lack of capacity to provide informed consent

Age < 18 years

Trial population

Inpatients in tuberculosis care

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • data collection

    Other intervention

    Prospective data collection in a clinical data registry

Treatment groups

1,000 Participants
are divided into 4 treatment groups
Group A: Extrapulmonary TB1 intervention
Group B: drug-resistant TB1 intervention
Group C: drug-susceptible TB1 intervention
Group D: TDM1 intervention

Trial outcomes

Primary outcomes

1

Extrapulmonary TB: Favourable treatment outcome

Identification of parameters that predict/are significantly associated with favorable outcome in EPTB

Time frame
December 2040
2

Drug-resistant TB: Description of treatment outcome

Percentage of patients cured, failed, died, under/after therapy according to WHO and TBnet outcome criteria

Time frame
December 2040
3

Drug-resistant TB: Description of treatment completion

Percentage of patients who develop serious/severe drug-related adverse events/who have to change regimen due to drug-related adverse events

Time frame
December 2040
4

Drug-susceptible TB: Mortality risk score

Development of a TB mortality risk score, defined by a final set of predictors and a weighted scoring system based on routine clinical, radiological, microbiological, and laboratory data.

Time frame
December 2040

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Research Center Borstel

Lead sponsor

European Society of Clinical Microbiology and Infectious Diseases

Collaborator

Tuberculosis Network European Trialsgroup (TBnet e.V.)

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: